Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, researchers have found that PD-1 in mice is ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Analogic Corp., the Peabody-based maker of medical and airport-security equipment, plans to move its headquarters and ...

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer ...

Immuno-oncology (IO) drugs or cancer therapeutics represent one of the most promising areas of medical innovation in the next ...

While frequent U.S. flyers may recognize optional face-scanning tech like TSA-approved Clear, Russia just rolled out a system ...

Fintel reports that on January 2, 2025, Goldman Sachs downgraded their outlook for Check Point Software Technologies ...

HIF1α identified as key regulator that induces cancer-killing ability of hypoxic T cells, playing a role in ICB resistance.

Goldman Sachs downgraded Check Point (CHKP) to Neutral from Buy with a price target of $207, up from $204. The firm believes the company’s ...

Check Point Software Technologies Ltd. (NASDAQ:CHKP – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short ...

Check Point (CHKP – Research Report) received a Hold rating and a $207.00 price target from Goldman Sachs analyst Gabriela Borges yesterday.